Anthelmintic activity of nanoencapsulated carvacryl acetate against gastrointestinal nematodes of sheep and its toxicity in rodents / Atividade anti-helmíntica do acetato de carvacrila nanoencapsulado sobre nematoides gastrintestinais de ovinos e toxicidade em roedores

Abstract The objective of this study was to evaluate the efficacy of carvacryl acetate (CVA) and nanoencapsulated CVA (nCVA) on gastrointestinal nematodes of sheep. The CVA was nanoencapsulated with chitosan/gum arabic and the efficacy of nanoencapsulation (EE), yield, zeta potential, nanoparticle morphology and release kinetics at pH 3 and 8 were analyzed. Acute and subchronic toxicity were evaluated in rodents and reduction of egg counts in the faeces (FECRT) of sheep. The sheep were divided into four groups (n = 10): G1, 250 mg/kg CVA; G2, 250 mg/kg nCVA; G3, polymer matrix and G4: 2.5 mg/kg monepantel. EE and nCVA yield were 65% and 57%, respectively. The morphology of the nanoparticles was spherical, size (810.6±286.7 nm), zeta potential in pH 3.2 (+18.3 mV) and the 50% release of CVA at pHs 3 and 8 occurred at 200 and 10 h, respectively. nCVA showed LD50 of 2,609 mg/kg. CVA, nCVA and monepantel reduced the number of eggs per gram of faeces (epg) by 57.7%, 51.1% and 97.7%, respectively. The epg of sheep treated with CVA and nCVA did not differ from the negative control (P>0.05). Nanoencapsulation reduced the toxicity of CVA; however, nCVA and CVA presented similar results in the FECRT.

Resumo O objetivo deste trabalho foi avaliar a eficácia do acetato de carvacrila (ACV) e do ACV nanoencapsulado (nACV) sobre nematóides gastrintestinais de ovinos. O ACV foi nanoencapsulado com quitosana/goma arábica e foi analisada a eficácia de nanoencapsulamento (EE), o rendimento, potencial zeta, morfologia das nanopartículas e cinética de liberação em pH 3 e 8. Foram avaliadas as toxicidades aguda e subcrônica em roedores e a redução da contagem de ovos nas fezes (RCOF) de ovinos. Os ovinos foram divididos em quatro grupos (n = 10): G1, 250 mg/kg ACV; G2, 250 mg/kg de nACV; G3, matriz polimérica e G4: 2,5 mg/kg de monepantel. A EE e o rendimento de nACV foram de 65% e 57%, respectivamente. A morfologia das nanopartículas foi esférica, tamanho (810,6±286,7 nm), potencial zeta no pH 3,2 (+18,3 mV) e a liberação de 50% de CVA nos pHs 3 e 8 ocorreu às 200 e 10 h, respectivamente. nACV apresentou DL50 de 2.609 mg/kg. ACV, nACV e o monepantel reduziram a contagem de ovos por grama de fezes (opg) em 57,7%, 51,1% e 97,7%, respectivamente. A contagem de opg de ovelhas tratadas com ACV e nCVA não diferiu do controle negativo (P>0,05). O nanoencapsulamento reduziu a toxicidade do AVC; no entanto, nACV e ACV apresentaram resultados semelhantes na RCOF.

Developments in the use of nanocapsules in oncology

The application of nanotechnology to medicine can provide important benefits, especially in oncology, a fact that has resulted in the emergence of a new field called Nanooncology. Nanoparticles can be engineered to incorporate a wide variety of chemotherapeutic or diagnostic agents. A nanocapsule is a vesicular system that exhibits a typical core-shell structure in which active molecules are confined to a reservoir or within a cavity that is surrounded by a polymer membrane or coating. Delivery systems based on nanocapsules are usually transported to a targeted tumor site and then release their contents upon change in environmental conditions. An effective delivery of the therapeutic agent to the tumor site and to the infiltrating tumor cells is difficult to achieve in many cancer treatments. Therefore, new devices are being developed to facilitate intratumoral distribution, to protect the active agent from premature degradation and to allow its sustained and controlled release. This review focuses on recent studies on the use of nanocapsules for cancer therapy and diagnosis.

Tuberculosis experimental y nanopartículas de las drogas específicas / Experimental tuberculosis and nanoparticles of specific drugs

La tuberculosis (TB) sigue siendo un problema epidemiológico dificil de controlar, especialmente en los países en vías de desarrollo. Por ello, será bienvenido todo lo que implique una mejoría en su manejo. La incorporación de las nanopartículas a la medicina, producida en los últimos años, puede traer aparejada ventajas en su diagnóstico y tratamiento, así como un control en el número creciente de pacientes enfermos con gérmenes multirresistentes a las drogas específicas. Se actualiza en esta publicación que, en diversos países del mundo, animales de laboratorio, cobayos y ratones, inoculados por el Mycobacterium tuberculosis, tuvieron mejorías llamativas de su enfermedad o su esterilización después de ser tratados con las drogas específicas (Isoniacida, Rifampicina, Pirazinamida y Estreptomicina) suministradas como nanopartículas. No se han efectuado hasta ahora experimentos en tuberculosis humana, pero las posibilidades son promisorias. Las nanopartículas tienen varias ventajas terapéuticas: gran estabilidad, gran capacidad para conducir múltiples drogas, varias vías de administración (inhalatoria, oral, intravenosa y subcutánea). Esperamos que en un futuro próximo podamos asistir a mejoras en el manejo de la tuberculosis humana.

Tuberculosis (TB) continues to be a difficult to control epidemiologic problem, particularly in the developing countries. For such reason, anything that may imply an improvement in its management will be welcome. The adoption of nanoparticles by the medical science, over the last few years, may entail advantages regarding its diagnosis and treatment as well as a control of the increasing number of patients infected with specific drug multi-resistant germs. The present publication introduces the information that in several countries laboratory animals, guinea-pigs and mice, inoculated with Mycobacterium tuberculosis, either showed striking recoveries or the sterilization of their disease after being treated with the specific drugs (Isoniazid, Rifampycin, Pyrazinamide and Streptomycin) administered as nanoparticles. No experiments have been made to date in human tuberculosis but there exist promising possibilities. Nanoparticles have several therapeutic advantages: great stability, a large capacity to carry multiple drugs, different routes of administration (inhalatory,oral, intravenous and subcutaneous). We expect that in the near future we will be able to see an improvement in the management of human tuberculosis.

Future Direction of Nanomedicine in Gastrointestinal Cancer / 대한소화기학회지

Cancer is one of the leading causes of death in human, and among various cancers, gastrointestinal cancers occupy more than 55%. Gastric cancer is the first leading cause of cancer-related mortality in the world and the number of pancreas and colon cancers are increasing remarkably during last two decades which will continue to increase in the future. Even though the clinical importance of gastrointestinal cancers is very high and endless efforts has been made to develop novel diagnostic and therapeutic methods to improve the patient's quality of life and survival, the realistic advance in the actual survival benefit of the cancer patients are still strongly required. Nanotechnology has the power to radically change the way of cancer diagnosis and treatment. Currently, there is a lot of researches on novel nanodevices capable of detecting cancer at its earliest stage, pinpointing its location within the body, and delivering anticancer drugs specifically to the malignant cells. Nanoscale devices can readily interact with biomolecules both on the cell surface and within the cell. In addition, nanoscale devices are already proven that they can deliver therapeutic agents to target cells even within specific organelles. Major areas in which nanomedicine is being developed in cancer include early detection and proteomics, imaging diagnostics and multifunctional therapeutics. Because nanotechnology would provide a technical power and tool that enable new diagnostics, therapeutics, and preventives to keep pace with today's explosion in knowledge in the future, it would be very useful to know the perspectives in the direction of nanotechnology as a major clinician responsible for the patients with gastrointestinal malignancies.